Shares of ViaDerma (OTCMKTS: VDRM) gained almost 1,000% as the market approached Wednesday, after the pharmaceutical company released its 2020 update and 2021 status. flying word. With that in mind, what should you know about these penny stock stories now?
To begin with, investors need to know that ViaDerma is a specialized pharmaceutical company. This is one of the reasons why VDRM stock is so rare, in addition to its penny-stock status.
With that in mind, here’s what you need to know about ViaDerma and VDRM stock now:
Very low VDRM Stock shares.
So what should you do with ViaDerma stock and VDRM? And why are stocks rising on Wednesday?
Upward movement is possible due to the company’s 2021 situation. On release, ViaDerma acknowledged that 2020 was a strong year. Introduced a new pain reliever, made some money and saw great clients who might check out their Vitastem signature.
If we look at 2021 then, that means there is a chance for ViaDerma to use its success from 2020 and reap additional benefits. However, like any penny stock, and especially those in the biopharma space, tread carefully. As soon as the stock runs out, the next minute those profits may go away.
At the time of publication, Sarah Smith did not have (directly or indirectly) any of the securities mentioned in this article.
Aside from the unusual ones, Investor Place does not publish comments about companies with a market limit of less than $ 100 million or trading less than 100,000 shares each day. This is because these “penny stocks” are often the playground of fraudulent artists and market fraudsters. In the event that we publish a comment on a low-volume stock that may be affected by our analysis, we would like the authors of sportpokers.com to disclose this fact and warn readers of the risks.